Faculty

Researcher Michael Berger focuses on massively parallel sequencing of tumor DNA for biomarker discovery and clinical diagnostics.

Cancer biologist Nikolaus Schultz uses computational tools to study the diversity of genomic alterations underlying different cancer types.

Physician-scientist Omar Abdel-Wahab studies the functional genomics of hematopoietic malignancies.

Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.

The Lito lab investigates the properties of oncoproteins that drive cancer cell growth, with a focus on cancers driven by RAS mutations.

Physician-scientist Rachel Niec studies how cells and tissues communicate to promote health or drive inflammation and cancer.

Mechanisms of genetic and epigenetic cooperativity which drive myeloid transformation; Elucidating and modeling evolution from hematopoietic stem/progenitor cells to clonal hematopoiesis and then to myeloid malignancies; Identification and credentialing novel therapeutic dependencies in myeloid malignancies

Physician-scientist Samuel Singer studies the genomic alterations that define new targets for therapy in sarcoma. I am a surgical oncologist who specializes in the diagnosis and treatment of soft tissue sarcoma. I have extensive experience with this group of cancers, and am one of just a few surgeons in the world focused solely on treating sarcoma patients. My years of experience have enabled me to devise surgical techniques that improve the ability to completely remove these tumors. In addition to my clinical sarcoma practice, I conduct laboratory research to develop new methods to improve the diagnosis and treatment of sarcoma. I lead both a National Cancer Institute Specialized Program in Research Excellence (SPORE) and the Sarcoma Genome Project.

Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.

Physician-scientist Yu Chen studies the role of transcription factors that are critical for prostate cancer development.